Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Twelve Weeks of Pioglitazone Therapy Significantly Attenuates Dysmetabolism and Reduces Inflammation in Prevalent Peritoneal Dialysis Patients. A Randomized, Cross-over Trial.

NCT01258322 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT01258322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01258322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Twelve Weeks of Pioglitazone Therapy Significantly Attenuates Dysmetabolism and Reduces Inflammation in Prevalent Peritoneal Dialysis Patients. A Randomized, Cross-over Trial.
Lead sponsor
Huashan Hospital
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2008
Completion date
September 30, 2008
Enrollment
70 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia, inflammation, insulin resistance, peritoneal dialysis, pioglitazone